Another thought is that ttf company(s) would be more comparable to radiation modalities so valuation process more like varian or elektra. Not sure if there is a pure p-beam company. However, nvcr is not getting push back yet on pricing like cancer drug.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.